저자의 연구 키워드

저자의 연구 키워드

#5-fluorouracil

#Abscopal effect

#Acute kidney injury

#Adenocarcinoma

#Adenocarcinoma in situ

#Adenoid cystic carcinoma

#Adjuvant chemotherapy

#Alectinib

#Anaplastic lymphoma kinase

#Angiogenesis

#Anti?PD-1

#Axitinib

#Biomarkers

#BRAF

#BRAFV600E

#Brain

#Brain metastasis

#Brigatinib

#cancer

#Cancer pain

#Capecitabine

#Carcinoma

#Chemoradiotherapy

#Chemotherapy

#Cisplatin

#Clinical benefit response

#Clinical trial

#Clinical trials

#Colorectal neoplasm

#Colorectal neoplasms

#Combination chemotherapy

#Concurrent chemo-radiation therapy

#Concurrent chemoradiotherapy

#Cost analysis

#Dabrafenib

#Derivatives

#Disease progression

#Disease-free survival

#Docetaxel

#Drug therapy

#Durvalumab

#East Asian

#EGFR mutant NSCLC

#EGFR mutation

#EGFR-TKI

#epidermal growth factor

#Epidermal growth factor receptor

#ErbB receptors

#Esophageal neoplasms

#Etoposide

#Far East

#Fluorodeoxyglucose F18

#Fluorouracil

#FOLFOX

#Gastric neoplasm

#Gefitinib

#Gemcitabine

#Ground-glass nodule

#Head and neck neoplasms

#Heparin

#Hepatic metastasis

#Heptaplatin

#Human papillomavirus

#hypercoagulability

#Hyperuricemia

#Immune check point

#Immune checkpoint inhibitor

#Immune therapy

#immunocompromised host

#Immunohistochemistry

#Immunotherapy

#Investigator-initiated clinical trial

#Investigator-initiated trials

#Irinotecan

#Ischemic stroke

#Korea

#Korean Cancer Study Group

#KRAS

#Lazertinib

#Lepidic

#Leptomeningeal metastasis

#Leucovorin

#locoregional recurrence

#Lung

#Lung neoplasms

#Maintenance chemotherapy

#Mesothelioma

#Metachronous

#Metastasis

#Metastatic colorectal cancer

#Metastaticcolorectal carcinoma

#mortality

#Mouse

#Mucinous adenocarcinoma

#Nasopharyngeal Carcinoma

#Necitumumab

#Neoplasms/drug therapy

#NGS

#Nintedanib

#non-small cell lung cancer

#Non-small cell lung carcinoma

#Non–small cell lung carcinoma

#non-small-cell lung

#Non–small-cell lung cancer

#Non-small-cell lung carcinoma

#Non–small-cell lung carcinoma

#Nonsquamous non-small cell lung carcinoma

#Oligorecurrence

#Oropharyngeal neoplasms

#Osimertinib

#Oxaliplatin

#p53

#Paclifaxel

#Pancreas neoplasm

#Papillary thyroid carcinoma

#pathogens

#Pembrolizumab

#Pemetrexed

#PIK3CA

#Platinum refractory

#Pleura

#pneumonia

#Positron-Emission Tomography

#Pralsetinib

#Precision medicine

#Prognosis

#Programmed death ligand 1

#Proton therapy

#radiation therapy

#Radiofrequency ablation

#Radiotherapy

#Real-world data

#Receptor

#RECIST

#Response Evaluation Criteria in Solid Tumors

#RET

#RET-rearrangement

#Salivary gland neoplasms

#salvage treatment

#severity of illness index

#Size

#Small cell lung carcinoma

#Sponsor-initiated clinical trial

#Squamous cell carcinoma of head and neck

#Stage IIIA-N2

#Subsolid nodule

#Sum of target lesions

#survival

#Survival analysis

#Systemic chemotherapy

#Targeted therapy

#Third-generation EGFR tyrosine kinase inhibitor

#Thymidine phosphor-ylase

#Thymidylate synthase

#Thymoma

#Thyroid neoplasms

#Trametinib

#Transdermal fentanyl

#Treatment outcome

#Tremelimumab

#Tumor Burden

#Tumor lysis syndrome

#Tumor response

#Tumor size

#Tyrosine kinase inhibitor

#Tyrosine kinase inhibitors

#Tyrosine-kinase inhibitor

#Umbrella trial

#Vascular endothelial growth factor A

#Vascular endothelial growth factor receptors

#WHO